Advertisement
News
Advertisement

STAAR Surgical Launches New Visian ICL™ Product Line Extensions at ESCRS

Wed, 09/08/2010 - 3:33am
Bio-Medicine.Org

MONROVIA, Calif., Sept. 8 /PRNewswire/ -- STAAR Surgical Company (Nasdaq: STAA), the leading worldwide developer, manufacturer and marketer of phakic intraocular lenses, today announced that the Visian Implantable Collamer® Lens (ICL) was featured prominently in more than 40 presentations by leading ophthalmologists at meetings prior to and during the 2010 Congress of European Society of Cataract and Refractive Surgeons (ESCRS) held in Paris, France from September 4 through 8, 2010.  The presentations, based on studies conducted by surgeons throughout the world, confirmed that the Visian ICL offers superior visual results over a wide range of myopic and hyperopic refractive errors including those within the most popular LASIK areas of treatment.  These presentations also confirmed the safety and efficacy of the Visian ICL over a period of 17 years.  

The 7th Annual Visian ICL Expert Meeting, sponsored by STAAR, was held prior to the conference with 100 surgeons from 34 countries in attendance.  There were 26 presentations and eight specialized breakout sessions on ICL topics over a two-day period.  During the opening presentation Hans Blickensdoerfer, President of STAAR Europe, Latin America and the Middle East, demonstrated the growth in Visian ICL procedures by comparing the rate of ICL implants per minute.  In 2008, worldwide, a Visian ICL was implanted every 20 minutes; that rate has doubled in 2010 to one implant every 10 minutes.

"This was our seventh annual meeting of this type and I believe it was the best," commented Mr. Blickensdoerfer.  "We continue to see strong growth in the Visian ICL throughout the world and believe that the newly expanded Visian ICL diopter ranges launched here at ESCRS more than doubles the market opportunity for Visian and allow us to compete directly within the most popular myopic and hype

'/>"/>

SOURCE

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading